Education
About Us
Working with TipRanks
Follow Us
Joint Corp (JYNT)
NASDAQ:JYNT
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.03Last Year’s EPS
-0.03Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicates clear strategic progress (notably substantial refranchising toward a capital-light franchisor model, improved consolidated adjusted EBITDA, strong patient experience metrics, and definitive run-rate margin targets) while acknowledging meaningful near-term operational challenges (chiefly weak new-patient acquisition and Q4 comp declines). Management provided concrete actions—national marketing, SEO, pricing tests, conversion/retention programs, cost rightsizing—and a quantified view of expected post-refranchising profitability. Given the combination of current headwinds in new-patient flow but material improvements in profitability, balance-sheet actions, and a credible plan to complete refranchising (with projected step-up in margins), the positives modestly outweigh the negatives.Company Guidance
Progress on Joint 2.0 and Refranchising
Significant transformation progress toward becoming a pure-play franchisor: corporate-owned clinics reduced from 135 to 48 (now ~5% of portfolio). Signed asset purchase agreement for 22 clinics for $1.5M and an LOI for 5 clinics; management expects refranchising to complete mid-2026 and is in active conversations for remaining clinics.
Improved Consolidated Adjusted EBITDA and Net Income
Q4 consolidated adjusted EBITDA increased 7.8% to $3.6M versus prior-year Q4; full-year consolidated adjusted EBITDA rose 13.9% to $13.0M. Consolidated net income improved by $8.7M year-over-year to $2.9M (vs. $5.8M loss in 2024).
System-wide Sales and Full-Year Stability
Full-year system-wide sales were flat at $532.0M compared to prior year, providing a stable base as operational changes are implemented.
Share Repurchases and Liquidity Position
Q4 repurchased 1.1M shares for $9.0M and repurchased 1.3M shares for $11.3M in 2025 (avg ~$8.7/sh). Unrestricted cash ended Q4 at $23.6M and the company had a $20.0M undrawn revolving credit facility.
Operational and Patient Experience Improvements
New-clinic preopening protocol shortened time to breakeven (half the prior time). Patient app received strong feedback (4.91/5 from >23,000 responses) with intent to recommend 9.7/10; 75% of patients report wait times under five minutes.
Digital Marketing and Lead-Gen Momentum
Launched national media program (Nov) and completed microsite migration; organic traffic and high-intent actions (calls/submissions) are trending up. Early sequential monthly improvement in new-patient acquisition since program launch, supported by improved SEO visibility versus benchmarks.
Run-Rate Financial Targets as Pure-Play Franchisor
Projected post-refranchising run-rate: revenue capture ~11% of system-wide sales (vs 10.3% in 2025); gross margin 83-85%; G&A 40-42% (vs 64% in 2025); CapEx ~3%; free cash flow conversion 60-70%; estimated adjusted EBITDA margin 19-21% (vs 12% in 2025) and net income margin 13-15% (vs 3% in 2025).
2026 Guidance Provided
2026 targets: system-wide sales $540M–$552M; comp sales -3% to +3%; consolidated adjusted EBITDA $12.5M–$13.5M; company expects continuing operations to be more profitable in 2026 as refranchising reduces corporate cost base.
JYNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JYNT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | $8.21 | $8.40 | +2.31% |
Nov 06, 2025 | $7.98 | $7.67 | -3.88% |
Aug 07, 2025 | $10.70 | $10.74 | +0.37% |
May 08, 2025 | $10.53 | $9.99 | -5.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Joint Corp (JYNT) report earnings?
Joint Corp (JYNT) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Joint Corp (JYNT) earnings time?
Joint Corp (JYNT) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JYNT EPS forecast?
JYNT EPS forecast for the fiscal quarter 2026 (Q1) is 0.03.